Zydus Lifesciences Ltd.

Financial

	Zydus Lifesciences	Lupin	Dr. Reddy's Lab
Operational Metrics
API Sector
US DMF Filings	142.0 .	156.0 .	n/a
Pharmaceutical Sector
Number of ANDA's Filed in USA	483.0 .	430.0 .	354.0 .
Number of ANDA's Approved By USFDA	415.0 .	334.0 .	275.0 .
Domestic Sales Growth - YoY	9.4 %	7.3 %	9.3 %
R&D as a % of Total Sales	8.1 %	7.7 %	8.0 %
Financials
5 yr Average ROE	16.96 %	2.19 %	14.9 %
5yr average Equity Multiplier	1.66	1.79	1.41
5yr Average Asset Turnover Ratio	0.65	0.72	0.77
5yr Avg Net Profit Margin	16.78 %	1.82 %	14.03 %
Price to Book	4.06	6.14	3.26
P/E	19.51	33.5	18.66
5yr Avg Cash Conversion Cycle	-68.16 Days	-70.43 Days	64.1 Days
Inventory Days	44.51 Days	51.95 Days	75.39 Days
Days Receivable	46.37 Days	52.75 Days	99.54 Days
Days Payable	164.0 Days	155.88 Days	102.35 Days
5yr Average Interest Coverage Ratio	24.75	3.96	34.06
5yr Avg ROCE	17.68 %	8.04 %	19.83 %
5yr Avg Operating Profit Margin	22.37 %	12.57 %	21.19 %
5 yr average Debt to Equity	0.3	0.34	0.12
5yr CAGR Net Profit	26.82 %	n/a	22.45 %
5yr Average Return on Assets	10.66 %	1.4 %	10.71 %
Shareholdings
Promoter Holding	74.99 %	46.92 %	26.64 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.11 %	0.14 %	-0.08 %
Change in Mutual Fund Holding (3 Yrs)	0.81 %	1.83 %	-1.23 %

Business

	Zydus Lifesciences	Lupin	Dr. Reddy's Lab
Product Wise Break-Up	Product Wise Break-Up US Formulations 47.0 India Formulations 29.0 Wellness 9.0 Active Pharmaceutical Ingredient (API) 3.0 Alliance 1.0 Emerging Markets 0 Europe Formulatios 0 Animal Health 0 EMB Formulations 0 USA 0 Developed Markets 0 NCE licensing income 0 India 0 Emerging Market Formulation 0 Advanced Markets Formulations 0 Generic FDF 0 Custom Synthesis 0 Proprietary Products 0 Global Generics 0 0 Others 11.0	Product Wise Break-Up Europe Formulatios 0 Alliance 0 India 34.0 USA 0 Global Generics 0 Proprietary Products 0 Emerging Market 12.0 Advanced Markets Formulations 45.0 Emerging Markets 0 US Formulations 0 India Formulations 0 Generic FDF 0 EMB Formulations 0 Developed Markets 0 Wellness 0 NCD 1.0 Active Pharmaceutical Ingredient (API) 0 0 Animal Health 0 Custom Synthesis 0 Others 8.0	Product Wise Break-Up Europe Formulatios 0 Alliance 0 India 0 USA 0 Formulations 88.24 Proprietary 1.93 Emerging Market Formulation 0 Advanced Markets Formulations 0 Emerging Markets 0 US Formulations 0 India Formulations 0 Generic FDF 0 EMB Formulations 0 Developed Markets 0 Wellness 0 NCE licensing income 0 Active Pharmaceutical Ingredient (API) 0 Pharmaceutical 9.83 Animal Health 0 Custom Synthesis 0
Segment Break-Up	Segment Break-Up Pharmaceuticals 91.29 OTC 8.71 Research Services & Sale of IP`s 0	Segment Break-Up Research Services & Sale of IP`s 0 OTC 0 Pharmaceuticals 99.54 Others 0.46	-
Location Wise Break-Up	Location Wise Break-Up USA 44.89 India 41.0 API 0 EMEA 0 Growth Markets 0 Japan 0 Russia 0 Others 14.11	Location Wise Break-Up USA 38.0 Japan 0 API 5.0 Russia 0 Developed Markets 8.0 India 34.0 EMEA 11.0 Others 4.0	Location Wise Break-Up USA 48.56 Japan 0 API 0 Russia 7.99 Growth Markets 0 India 17.36 EMEA 0 Others 26.09
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 99.26 OTC 0.74 Proprietary Products 0 0 Global Generics 0	-	Operating Profit Break-Up OTC 0 Global Generics 92.18 Proprietary Products 3.01 Pharmaceutical Services and Active Ingredients 4.81 Pharmaceuticals 0
Therapeutic Area Break-Up	Therapeutic Area Break-Up Cardiac Science 16.0 Respiratory Systems 13.0 Anti-Infective 13.0 Gastro Intestinal 9.0 Pain Management 7.0 Gynecology 7.0 Dermatology 6.0 Central Nervous System 0 Cardiovascular 0 Oncology 0 Gastrointestinal 0 Others 29.0	-	Therapeutic Area Break-Up Respiratory Systems 0 Anti-Infective 6.48 Cardiac Science 0 Gastro Intestinal 9.52 Gastro Intestinal 0 Dermatology 3.13 Central Nervous System (CNS) 12.12 Cardiac Science 6.65 Oncology 27.53 Gynecology 0 Pain Management 9.77 Others 24.8
Asset Break-Up	Asset Break-Up India 94.06 USA 2.65 United States 0 Switzerland 0 Others 3.29	-	Asset Break-Up India 80.24 USA 0 USA 2.37 Switzerland 8.45 Others 8.94

Zydus Lifesciences Ltd.

SIGN UP FOR FREE